Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
- 16 January 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 27 (5), 482-489
- https://doi.org/10.1007/s10637-008-9217-1
Abstract
Multidrug chemotherapy increases responses in advanced soft tissues sarcoma. Can a 20% increase of relative dose intensity of the MAID regimen, more improve responses? From 1994 to 1997, 162 patients were randomized in a phase III study to the conventional drug combination (6 cycles of MAID: 60, 7,500, 900 mg/m2 for doxorubicin, ifosfamide and dacarbazine respectively), or at doses 20–33% higher per cycle (5 cycles of intensified MAID for similar cumulative doses) with systematic G-CSF. Primary endpoint was response rate; secondary were toxicity, event-free and overall survival. The objective response rate in assessable patients was 38% with intensified MAID and 35% with MAID (p = 0.72). Event-free and overall survivals were similar in both arms. Only grade 3–4 thrombocytopenia and anemia were significantly higher in intensified arm. Treatment with intensified MAID did not improve response rate neither survival and cannot be recommended for advanced or metastatic soft tissue sarcoma.Keywords
This publication has 28 references indexed in Scilit:
- Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcomaCancer, 2008
- Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJournal of Clinical Oncology, 2007
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyThe Lancet Oncology, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Soft-Tissue Sarcomas in AdultsNew England Journal of Medicine, 2005
- Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialJournal of Clinical Oncology, 2005
- Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma PatientsJournal of Clinical Oncology, 2004
- Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcomaEmergencias, 2003
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988